3.3 Analysis of maternal-fetal paired single nucleotide
polymorphisms
In order to figure out whether mother with Val66Met mutation will effect
the SNP of fetus, we performed mother-fetal pairing to explore whether
the site was transferred from mother to fetus. Tthe results of SNP
analysis in paired pregnant women were basically consistent with the
results obtained from large samples. The difference between the BDNF
gene Val66Met locus allele case group and the control group was
statistically significant (χ2=9.054, P=0.003, OR=0.630,
95%CI=0.466-1.852). However, there was no significant difference in
genotype (χ2 = 0.634, P = 0.728) and additive genes (χ2 = 0.477, P =
0.49, OR = 0.846, 95% CI = 0.525-1.362)(Table 3). Besides, Val66Met
loci in BDNF gene of newborns in paired samples showed no significant
difference in genotype distribution (χ2 = 1.883, P =
0.390), alleles (χ2 = 1.791, P = 0.181, OR = 1.208,
95% CI = 0.916-1.592) and additive genes ( χ2 =
1.407, P = 0.235, OR = 1.369, 95% CI = 0.814-2.304) between the two
groups(Table 4).
We wondering whether Val166Met may
have a potential impact on the occurrence of new born poor prognosis
associated with PE. So, we performed pairing classification for
maternal-fetal BDNF Val66Met locus phenotype. However, the results
showed that there was no significant difference between the case group
and the control group in the maternal-fetal transmission.
(χ2 = 4.896, P = 0.086). See Table 5.